Embeding & Securing Commercial Viral Vector Production within a CDMO environment

A single gene therapy treatment can cost hundreds of thousands of pounds, but the UK currently lacks the industrial-scale manufacturing capacity to produce the viral vectors—the modified viruses that deliver therapeutic genes into patients' cells—needed to supply both clinical trials and commercial markets. Cobra Biologics, a UK-based contract development and manufacturing organisation (CDMO), is expanding its facility in Keele to build that capacity. The problem is straightforward: early-stage clinical trials have shown that gene therapies can transform lives, but producing enough viral vector material quickly and reliably remains a bottleneck. Without dedicated commercial-scale manufacturing, these treatments cannot reach the patients who need them. If this expansion succeeds, the UK will gain world-leading capabilities for clinical and commercial viral vector production. The immediate impact is on the gene therapy supply chain—a system most people never think about, but one that determines whether innovative medicines move from academic labs to pharmacy shelves. The project will also integrate with existing UK infrastructure for translating academic discoveries into commercial realities, establishing the country as an internationally recognised centre of excellence in the field.